Poststreptococcal Glomerulonephritis (PSGN)

Elham Ramczanzadch , MD Associate Professor Of Nephrology GUMS

Poststreptococcal glomerulonephritis (PSGN) INTRODUCTION :

is caused by prior infection with specific nephritogenic strains of group A beta-hemolytic streptococcus.

 The clinical presentation of PSGN varies from asymptomatic, microscopic hematuria to the full-blown acute nephritic syndrome, characterized by red to brown urine, proteinuria (which can reach the nephrotic range), edema, hypertension, and acute kidney injury.

 The prognosis is generally favorable, especially in children, but in some cases, the long-term prognosis is not benign.

• EPIDEMIOLOGY

- Although PSGN continues to be the most common cause of acute nephritis in children globally, it primarily occurs in resource-limited countries.
- Of the estimated **470,000 new** annual cases of PSGN worldwide, **97 percent occur** in regions of the world with poor socioeconomic status, with an annual incidence that ranges from **9.5 to 28.5** per **100,000** individuals.
- In more developed and industrialized countries, the incidence has continued to decrease from the 1970s to the 1990s. The reasons may
 include the easier access to the treatment of streptococcal infections and the widespread presence of fluoride in water, which decreases
 virulence factors of Streptococcus pyogenes [7].
- The risk of PSGN is increased in older patients (greater than 60 years of age) and in children between 5 and 12 years of age .
- PSGN is uncommon in children less than **three years** of age.
- PSGN is twice as frequent in males as in females.

• EPIDEMIOLOGY

 PSGN can present as a sporadic case or during an epidemic of group A streptococcal (GAS) infection (ie, skin and throat infections). • PATHOGENESIS :

 Although the exact mechanisms of glomerular injury in PSGN have not yet been elucidated, they appear to be caused primarily by an autoimmune response to nephritogenic streptococcal antigens.

 This autoimmune response leads to immune complex formation and activation of the alternate complement pathway, which result in glomerular inflammation and injury.

Nephritogenic streptococcal antigens

Nephritis-associated Plasmin Receptor (Naplr) And Streptococcal Pyrogenic Exotoxin B (SPE B).

- NAPIr and SPE B can activate the alternate complement pathway and are capable of inducing chemotactic (monocyte chemoattractant protein 1) and IL-6 moieties in mesangial cells, promoting enhanced expression of adhesion molecules.
- •NAPIr NAPIr is a glycolytic enzyme which has glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity. NAPIr has a plasminlike activity which may promote a local inflammatory reaction. An elevated urinary plasmin activity has been observed in patients with acute PSGN.
- •SPE B SPE B is a cationic cysteine proteinase that has been localized to subepithelial deposits . SPE B deposition colocalized with complement deposition and within the subepithelial electron dense deposits (humps) that are characteristic of PSGN).
- Although the findings from this study support the role of SPE B as the more likely nephritogenic antigen, an alternate explanation is that separate antigens are responsible for PSGN in different parts of the world and/or in patients with varying genetic backgrounds.

Immune complex disease

 PSGN appears to be caused by glomerular immune complex disease induced by specific nephritogenic strains of group A beta-hemolytic streptococcus (GAS).

Nephritogenic streptococci strains 12, 4, and 1 are associated with PSGN triggered by throat infections, whereas PSGN secondary to skin infections is associated with strains 49, 42, 2, 57, and 60.

 The resulting glomerular immune complex disease triggers complement activation and inflammation.

Immune complex disease

- proposed mechanisms for the immunologic glomerular injury induced by GAS infection :
- <u>1</u>• Deposition of circulating immune complexes with streptococcal antigenic components.
- <u>2•</u>In situ immune complex formation resulting from deposition of streptococcal antigens within the GBM and subsequent antibody binding.
- <u>3•</u>In situ glomerular immune complex formation promoted by antibodies to streptococcal antigens that cross-react with glomerular components (molecular mimicry).
- Autoantibody formation leading to autoimmune reactivity –

Immune complex disease

- A number of autoantibodies have been detected in patients with PSGN [22]:
- Anti-factor B antibodies
- In one study of 34 children with acute PSGN and low complement levels, anti-factor B antibodies of the immunoglobulin G (IgG) one subclass were detected in 31 patients [23].
- Anti-factor B antibodies enhance the activity of the C3 convertase of the alternative pathway; their presence was inversely correlated with the levels of C3. In this study, the presence of anti-factor B antibodies had a sensitivity of 95 percent and a specificity of 82 percent for the diagnosis of PSGN.
- Anti-IgG Anti-IgG reactivity has been reported in patients with acute PSGN.

It is postulated that modification by **streptococcal neuraminidase** may modify immunoglobulins, rendering them autoantigenic.

This proposed mechanism is supported by the finding of **neuraminidase activity** and **free sialic acid levels** in plasma of patients with PSGN .

- Anti-DNA antibodies, antineutrophil cytoplasmic antibodies (ANCA), and anticardiolipin antibodies may also be found in some patients.
- The presence of anti-C1q antibodies has been found to be associated with more severe form and delayed resolution of the disease.
- -Rheumatoid factor (RF) RF is detected in two-thirds of patients with PSGN.

•Alternate complement pathway activation – Activation of the alternate complement pathway is a characteristic finding in PSGN. It is likely caused and enhanced by nephritogenic streptococcal antigens and autoantibodies.


- Light microscopy shows a diffuse proliferative and exudative glomerulonephritis with prominent endocapillary proliferation and numerous neutrophils (picture <u>2</u> and picture <u>3</u>).
- Trichrome stain may show small subepithelial hump-shaped deposits.

The severity of involvement varies and usually **correlates with** the clinical findings.

- Patients who are **asymptomatic** or have **mild** disease may have biopsies that show **little glomerular** involvement, whereas patients with diffuse endocapillary proliferative glomerulonephritis are more likely to **have full-blown acute nephritic syndrome** (ie, red to brown urine, proteinuria, edema, hypertension, and acute renal failure).
- Crescent formation is uncommon and is associated with a poor prognosis.

Kidney biopsy findings in poststreptococcal glomerulonephritis

Kidney biopsy findings in poststreptococcal glomerulonephritis




(A) Light microscopy showing a proliferative (exudative) glomerulonephritis. Note numerous neutrophils within glomerular capillaries (Periodic acid Schiff, 40x).

(B) Immunofluorescence microscopy showing bright granular capillary wall staining for C3 (40x).(C) Immunofluorescence microscopy showing bright granular capillary wall staining for IgG (40x).

Postinfectious glomerulonephritis

Postinfectious glomerulonephritis



Immunofluorescence microscopy

Immunofluorescence microscopy shows granular deposition of complement in the glomerular tuft in postinfectious glomerulonephritis. Immunoglobulin G (IgG) can also be seen in the same distribution.


- IF microscopy reveals a characteristic pattern of deposits of C3 and IgG distributed in a diffuse granular pattern within the mesangium and glomerular capillary walls.
- The granular pattern of C3 deposition in the capillary walls (garland-type deposits) gives a "starry sky" pattern.
- Other immune reactants (eg, immunoglobulin M [IgM], immunoglobulin A [IgA], fibrin, and other complement components) may also be detected.

- The **most characteristic** feature detected by EM are the dome-shaped **subepithelial** electron-dense deposits that are referred to as **humps**.
- These deposits along with **subendothelial deposits** are immune complexes and correspond to the deposits of **IgG** and **C3** found on IF.
- Subendothelial immune deposits and subsequent complement activation are responsible for the local influx of inflammatory cells, leading to a proliferative glomerulonephritis, an active urine sediment, and a variable decline in GFR.
- **Subepithelial "humps"** are responsible for epithelial cell damage and proteinuria, similar to that seen in membranous nephropathy.
- It has been proposed that the clinical course of PSGN is related to the different rates of clearance of immune complexes at **these two sites**.

Electron microscopy :

Electron micrograph of postinfectious glomerulonephritis

Electron micrograph shows subepithelial deposits (D) with a semilunar, hump-shaped appearance in postinfectious glomerulonephritis. The humps sit on top of the glomerular basement membrane (GBM). A neutrophil is attached to the denuded GBM, contributing to the glomerular inflammation. Neutrophil attraction requires the initial presence of subepithelial immune deposits so that complement chemoattractants have access to the systemic circulation.



CLINICAL MANIFESTATIONS

- The clinical presentation varies from
- asymptomatic,
- microscopic hematuria to the
- *full-blown* acute nephritic syndrome, characterized by red to brown urine, proteinuria (which can reach the nephrotic range), edema, hypertension, and an elevation in serum creatinine .
- However, most children are asymptomatic, as illustrated by a study of 248 children with group A streptococcal (GAS) infection, of whom 20 developed urinary abnormalities and a transient decrease in serum complement activity, but only one of whom was clinically symptomatic.
- A course of rapidly progressive ("crescentic") glomerulonephritis occurs in less than 0.5 percent of cases.
- There is usually an antecedent history of a GAS skin or throat infection.
- The latent period between GAS infection and PSGN is dependent upon the site of infection: between one and three weeks following GAS pharyngitis and between three and six weeks following GAS skin infection.

The following symptoms are the most common presenting signs in children :

- Edema Generalized edema is present in approximately two-thirds of patients due to sodium and water retention. In severe cases, fluid overload leads to respiratory distress due to pulmonary edema.
- Gross hematuria Gross hematuria is present in approximately 30 to 50 percent of patients. The urine looks smoky, and tea or cola colored.
- Hypertension Hypertension is present in 50 to 90 percent of patients and varies from mild to severe. It is primarily caused by salt and fluid retention. Hypertensive encephalopathy is an uncommon but serious complication. Magnetic resonance imaging (MRI) may show posterior reversible leukoencephalopathy [<u>37,38</u>]. These patients require emergent intervention.
- Subclinical cases of PSGN are primarily characterized by microscopic hematuria . Such patients were often detected during epidemics.
- Some patients present with hypertensive encephalopathy or acute pulmonary edema with minor urine abnormalities.

Laboratory findings

Renal function :

a **variable decline** in GFR... **AKI** develops in approximately **20 percent of** cases ,but uncommonly requires dialysis

• Urinalysis and urinary protein excretion :

- hematuria (some of the red cells are typically dysmorphic) with or without red blood cell casts (<u>picture 5</u> and <u>picture 6</u> and <u>picture 7</u>), varying degrees of **proteinuria**, and often pyuria.
- Nephrotic range proteinuria (defined as ≥1000 mg/m² per day or 40 mg/m² per hour) is uncommon and occurs in approximately 5 percent of cases at presentation.

Laboratory findings

- Complement : In approximately 90 percent of patients, C3 and CH50 (total complement activity) are significantly depressed in the first two weeks of the disease course.
- As C4 is usually within normal values, low C3 is the result of the activation of the alternative pathway due to the presence of factor B autoantibodies .
- **C4 and C2 levels** may be low in some patients, which suggests activation of both classical and alternative pathways [46].
- The C3 and CH50 return to normal within four to eight weeks after presentation.
- Culture Because PSGN presents weeks after an antecedent GAS infection, only approximately 25 percent of patients will have either a positive throat or skin culture [8]. In patients with impetigo, there is an increased likelihood of obtaining a positive skin culture [32].

Serology :

- Elevated titers of antibodies to extracellular streptococcal products are evidence of a recent GAS infection.
- The best markers for PSGN are serum antibody levels to NAPIr or SPEB/zSPEB, but these tests are rarely available .
- The streptozyme test, which measures five different streptococcal antibodies, is positive in more than 0.95 percent of patients due to
 pharyngitis and approximately 80 percent of those with skin infections.
- Anti-streptolysin (ASO)
- Anti-hyaluronidase (AHase)
- Anti-streptokinase (ASKase)
- Anti-nicotinamide-adenine dinucleotidase (anti-NAD)
- Anti-DNase B antibodies
- These antibodies can also be measured individually.
- After a pharyngeal infection, the ASO, anti-DNase B, anti-NAD, and AHase titers are commonly elevated.
- In comparison, only the anti-DNase B and AHase titers are typically increased after a skin infection.
- If only the ASO titer is used to screen for GAS infection, it may be falsely low or negative in patients with skin infections. It remains a
 useful test in patients with PSGN due to GAS pharyngitis but in some cases, the rise in ASO titer may be blunted in patients with
 pharyngitis who have received antimicrobial therapy.

DIAGNOSIS:

- PSGN is usually diagnosed based upon clinical findings of acute nephritis and demonstration of a recent group A beta-hemolytic streptococcal (GAS) infection.
- The clinical findings of acute nephritis include hematuria with or without red blood cell casts, variable degrees of
 proteinuria, edema, oliguria, and hypertension.

Documentation of a recent GAS infection includes either a positive throat or skin **culture** or **serologic** tests (eg, antistreptolysin [ASO] or streptozyme test).

- Although a low C3 and/or CH50 (total complement) level are consistent with a diagnosis of PSGN, these complement components may also be decreased in other forms of glomerulonephritis, including membranoproliferative glomerulonephritis.
- The authors concluded that acute nephritis needs to be considered in any child who presents with symptoms secondary to
 volume overload and that a urinalysis should be obtained as an initial diagnostic test.
- Renal biopsy is not performed in most patients to confirm the diagnosis of PSGN, since the resolution of PSGN typically begins within one week of presentation.

DIFFERENTIAL DIAGNOSIS:

- The diagnosis of PSGN is generally straightforward in patients once the diagnosis of acute nephritis is made, there is documentation of a recent group A beta-hemolytic streptococcal (GAS) infection, and the nephritis begins to resolve within one or two weeks of presentation.
- However, if there is progressive disease beyond two weeks,
- persistent hematuria or hypertension beyond four or six weeks, or
- there is not adequate documentation of an antecedent GAS infection,
- the following causes of glomerulonephritis (GN) need to be considered.

DIFFERENTIAL DIAGNOSIS:

A renal biopsy may be needed to differentiate PSGN from these other disorders:

- C3 glomerulopathy The presentation of C3 glomerulopathy may be indistinguishable initially from PSGN. It typically presents with hematuria, hypertension, proteinuria, and hypocomplementemia, which may follow an upper respiratory infection in some patients. However, patients with C3 glomerulopathy continue to have persistent urinary abnormalities and hypocomplementemia beyond four to six weeks and possibly a further elevation in serum creatinine. In contrast, patients with PSGN typically have resolution of their disease and a return of normal C3 and CH50 levels. (
- IgA nephropathy Patients with IgA nephropathy often present after an upper respiratory infection, similar to the presentation of patients with PSGN. Potential distinguishing features from PSGN include a shorter time between the antecedent illness and hematuria (less than 5 versus more than 10 days in PSGN) and a history of prior episodes of gross hematuria since recurrence is rare in PSGN.
- Secondary causes of glomerulonephritis Lupus nephritis and IgA vasculitis (IgAV; Henoch-Schönlein purpura [HSP]) nephritis share similar features to PSGN. However, extrarenal manifestations of the underlying systemic diseases and laboratory testing should differentiate them from PSGN. Measurement of serum complement may also be helpful. Hypocomplementemia is not observed in patients with IgAV (HSP) and the hypocomplementemia that occurs in lupus nephritis is, as mentioned above, associated with reductions in both C3 and C4, whereas C4 levels are usually normal in PSGN.
- Both hepatitis B and endocarditis-associated glomerulonephritis share common features with PSGN and also will present with reductions in C3 and C4.
- Postinfectious GN due to other microbial agents Acute nephritis due to viral and other bacterial agents has been reported (<u>table 1</u>). The clinical presentation is similar to that of PSGN except that there is no documentation of an antecedent GAS infection.

Antibiotic therapy

- If the streptococcal infection is still present at the time of diagnosis, penicillin therapy should be given (or in allergic patients, <u>erythromycin</u>).
- **Preventive antibiotic** treatment may be indicated in case of an epidemic situation or for household members of index cases .

Supportive care

- There is no specific therapy for PSGN. Management is supportive and is focused on treating the clinical manifestations
 of the disease, particularly complications due to volume overload. These include hypertension and, less commonly,
 pulmonary edema. General measures include sodium and water restriction and loop diuretics.
- Infrequently, patients have hypertensive encephalopathy due to severe hypertension. These patients should be treated
 emergently to reduce their blood pressure. Oral <u>nifedipine</u> or parenteral <u>nicardipine</u> are effective, while angiotensinconverting enzyme (ACE) inhibitors should be used with caution due to the risk of hyperkalemia.
- Patients with PSGN have variable reductions in renal function, and some patients require dialysis during the acute episode.
- Patients with evidence of recurrent group A streptococcal (GAS) infection should be given a course of antibiotic therapy.

Renal biopsy :

- In the acute setting, because it is unusual for patients with PSGN to require dialysis, a renal biopsy is performed in patients with significant renal impairment who require or are progressing towards dialysis treatment to confirm the diagnosis of PSGN.
- A renal biopsy is also indicated in cases of normal levels of C3 at presentation or when C3 remains low after one month.

 Patients with more than 30 percent crescents on renal biopsy are often treated with <u>methylprednisolone</u> pulses, although there is no evidence that aggressive immunosuppressive therapy has a beneficial effect in patients with rapidly progressive crescentic disease [54].

COURSE AND FOLLOW-UP

 Resolution of the clinical manifestations of PSGN is generally quite rapid, assuming concurrent resolution of the infection.

- A diuresis typically begins within one week, and the serum creatinine returns to the previous baseline by three to four weeks.
- Urinary abnormalities disappear at differing rates.
- Hematuria usually resolves within three to six months.
- Proteinuria usually disappears earlier than microscopic hematuria.
- In severe cases with nephrotic range proteinuria (defined as ≥1000 mg/m² per day or 40 mg/m² per hour), this degree
 of proteinuria may persist for six months or more, long after the hematuria has disappeared.

Correlation with histologic recovery :

- The histologic course **parallels** the improvements seen **clinically**.
- There is a marked reduction in the number of inflammatory cells in the glomeruli and the number of immune deposits seen on EM as the clinical manifestations resolve.

- The prolonged resolution of proteinuria compared with the **more rapid return** of renal function and remission of hematuria probably reflects the **slower rate of clearance of subepithelial compared with subendothelial immune complexes.**
 - •Subendothelial immune complexes are rapidly cleared by the inflammatory cells from the systemic circulation, thereby accounting for the resolution of hematuria and renal insufficiency. They may not be seen on renal biopsy unless performed early in the course.
- Subepithelial deposits are separated from circulating inflammatory cells by the glomerular basement membrane, thereby limiting their rate of removal . In general, the degree of proteinuria correlates with the number of subepithelial deposits .
- Recurrence Recurrent episodes of PSGN are rare. This may be due to the long-term persistence of antibodies to nephritis-associated streptococcal antigens.

ROGNOSIS :

- Most patients, particularly children, have an excellent outcome. This is true even in patients who present with acute renal failure and may have crescents on the initial renal biopsy.
- A review of three case series of 229 children with PSGN found that approximately 20 percent had an abnormal urinalysis (proteinuria and/or hematuria), but almost all (92 to 99 percent) had normal or only modestly reduced renal function 5 to 18 years after presentation.
- However, the long-term prognosis of PSGN is not always benign.
- Some patients, particularly adults, develop hypertension, recurrent proteinuria (with a relatively normal urine sediment), and renal insufficiency as long as 10 to 40 years after the initial illness.
- These late renal complications are associated with glomerulosclerosis on renal biopsy, which is thought to be hemodynamically mediated. According to this hypothesis, some glomeruli are irreversibly damaged during the acute episode and compensatory hyperfiltration in the remaining glomeruli maintains a relatively normal GFR.
- However, this adaptive response results in increases in glomerular pressure and size, both of which may then contribute to nonimmunologic glomerular injury and progressive renal dysfunction. It is possible that, in those patients who develop glomerulosclerosis, renal damage can be prevented or ameliorated by antihypertensive therapy (preferentially with an ACE inhibitor).

THANK YOU